Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, MD, ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

Immutep Limited (NASDAQ:IMMP) shares plunged roughly 80% on Friday after the biotechnology company announced it would ...

If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Survival outcomes in non-small cell lung cancer: Real-world analysis of immunotherapy era vs pre-immunotherapy era, with insights into treatment settings, racial disparities, and socioeconomic impacts ...

GBC-11004: An AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.

NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...